Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates

ReachMD Healthcare Image
Media formats available:
Details
Presenters
  • Overview

    This activity is not accredited for CME credit.

    Dr. Jürgen Floege, co-chair of the KDIGO Work Group, reviews the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV) emphasizing diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion emphasizes the new KDIGO proteinuria treatment goal of <0.3 g/d, and the utilization of combination therapy targeting immune modulation and CKD management. In addition, Dr. Floege highlights the use of sparsentan, a dual endothelin angiotensin receptor antagonist (DEARA), now recommended as a first-line treatment where approved.

  • Provider(s)/Educational Partner(s)


    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum. 

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor. 

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying Medtelligence…
but how about a more personalized experience?

Register for free